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Abstract
Background: The clinical significance and cellular sources of residual human immunodeficiency virus type 1 (HIV-1)
production despite suppressive combination antiretroviral therapy (cART) remain unclear and the effect of low-level viremia
on T-cell homeostasis is still debated.
Methodology/Principal Findings: We characterized the recently produced residual viruses in the plasma and short-lived
blood monocytes of 23 patients with various immunological responses to sustained suppressive cART. We quantified the
residual HIV-1 in the plasma below 50 copies/ml, and in the CD14
high CD16
2 and CD16
+ monocyte subsets sorted by flow
cytometry, and predicted coreceptor usage by genotyping V3 env sequences. We detected residual viremia in the plasma
of 8 of 10 patients with poor CD4
+ T-cell reconstitution in response to cART and in only 5 of 13 patients with good CD4
+ T-
cell reconstitution. CXCR4-using viruses were frequent among the recently produced viruses in the plasma and in the main
CD14
high CD16
2 monocyte subset. Finally, the residual viremia was correlated with persistent CD4
+ and CD8
+ T-cell
activation in patients with poor immune reconstitution.
Conclusions: Low-level viremia could result from the release of archived viruses from cellular reservoirs and/or from
ongoing virus replication in some patients. The compartmentalization of the viruses between the plasma and the blood
monocytes suggests at least two origins of residual virus production during effective cART. CXCR4-using viruses might be
produced preferentially in patients on cART. Our results also suggest that low-level HIV-1 production in some patients may
contribute to persistent immune dysfunction despite cART.
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Introduction
Treatment of human immunodeficiency virus type-1 (HIV-1)
with combined antiretroviral therapy (cART) decreases the plasma
HIV-1 RNA load to below the detection limit of standard assays
(,50 copies/ml), resulting in dramatic improvements in the
clinical course of HIV-1 infection. However HIV-1 cannot be
eradicated from infected individuals by current regimens and low
levels of HIV-1 RNA in the plasma can be detected using
extremely sensitive reverse transcriptase assays, even in patients on
prolonged effective cART [1–7]. This residual viremia may
indicate active virus production, as the half life of free virus
particles is short [8,9]. The cellular sources and the clinical
significance of persistent low-level viremia below 50 copies per ml
of plasma are not well-defined. The residual viremia could be due
to low-level replication that continues despite cART [3,10–14]
and/or the release of viruses from latently infected cells [14–18].
While resting memoryCD4
+T-cellsare the most significant cellular
reservoir for HIV-1 [19–25], other reservoirs can contribute to virus
persistence.Poor penetration or the active efflux of antiretroviral drugs
may allow the virus to continue replicating in certain anatomical or
cellular compartments. During cART, HIV-1 has been found to
persist in cells such as naı ¨ve CD4
+ T-cells [19,26–28], tissue
macrophages [29,30], and peripheral blood monocytes [31–35].
Blood monocytes, derived from mononuclear phagocytic precursor
cells in the bone marrow, may circulate in the peripheral blood for one
to three days before they differentiate into immature dendritic cells
and tissue macrophages [36,37]. Thus, persistent HIV-1 in blood
monocytes suggests recent infection and/or ongoing replication in
monocytes or in their precursor cells. Indirect evidence for ongoing
virus replication in patients on suppressive cART also includes the
detection of unintegrated HIV-1 DNA [21,38,39], cell-associated
HIV-1 RNA [11,12,32,40], and significant genetic evolution of HIV-1
sequences [40–42].
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allow genetic evolution of the virus quasispecies, and changes in
virus coreceptor use. Our previous five-year longitudinal study
found that CXCR4-using HIV-1 could be gradually selected in
cellular reservoirs during sustained effective cART, and that the
presence of CXCR4-using viruses could be associated with
impaired CD4
+ T-cell restoration [43]. Because of the differential
expression of HIV-1 coreceptors CCR5 and CXCR4 on distinct
T-cells subsets [44], the residual replication of CCR5- and
CXCR4-using viruses could have different impacts on T-cell
homeostasis during immune reconstitution on cART. The
interplay between virus tropism and CD4
+ T-cell restoration on
cART was previously examined by comparing the virological and
immunological features of two groups of patients, one having poor
CD4
+ T-cells restoration despite a sustained virological response
and the second having good immunological and virological
responses (ANRS EP32 study) [28]. This study suggests that the
persistent CD4
+ T-cell lymphopenia in the poor immunological
responders was mainly due to persistent T-cell activation and
apoptosis on cART, and this was associated with a high frequency
of CXCR4-using viruses in the peripheral blood mononuclear cells
(PBMCs) of the poor immunological responders.
We have now analyzed the residual production of HIV-1 in
patients on effective cART by characterizing the plasma and
monocyte compartments of 23 patients from the ANRS EP32
study. We measured residual plasma viremia below 50 copies/ml
using an ultrasensitive assay with a detection limit of 2.5 copies/ml
and characterized coreceptor use by amplifying V3 env with the
same detection sensitivity. The residual HIV-1 sequences found in
the plasma were compared to the sequences in CD14
high CD16
2
and CD16
+ monocytes and CD4
+ T-cells. Finally, we assessed
whether residual HIV-1 viremia could have a significant impact
on the T-cell homeostasis of patients on sustained cART, and
particularly whether it could be related to the persistent T-cell
activation that occurs in the poor immunological responders.
Materials and Methods
Study subjects and samples
Subjects were selected from HIV-1 infected patients character-
ized in the ANRS EP32 study [28]. This study compared two
groups of 15 patients, one having poor CD4
+ T-cell restoration
(gain of ,200 CD4
+ T-cells/ml) despite a sustained virological
response and the second having good immunological (gain of
.500 CD4
+ T-cells/ml) and virological responses. We excluded
two patients in each group because of non-subtype B HIV-1
infection, and three additional patients in the poor immunological
responder group because no cryopreserved plasma samples were
available. We thus studied 10 poor immunological responders and
13 good immunological responders. All of these patients had been
on cART for a median of 84 months at the time of analysis
(interquartile range, IQR [60–94]), and had had a sustained
undetectable plasma virus load throughout follow-up. The patient
characteristics are shown in Table S1 in the supplemental
material. We analysed cryopreserved samples taken before these
patients began cART and while they were on effective cART to
characterize the residual HIV-1 in the plasma and the monocyte
and CD4
+ T-cell compartments.
Ethics Statement
This research was approved by the Institutional Review Boards
of Toulouse University Hospital and the Pasteur Institute of Paris,
France. Written informed consent was obtained from all the
participants in this study.
Characterization of HIV-1 residual viremia below
50 copies/ml of plasma
Viral RNA extraction. Plasma samples (12 ml) were
centrifuged to remove contaminating cells and then ultracen-
trifuged at 20 000 g for 75 min at 4uC to collect the virus particles.
Viral RNA was then isolated using the QIAamp UltraSens Virus
Kit (Qiagen). Half of the extracted RNA (equivalent to 6 ml of
plasma) was used to quantify HIV-1 by real-time RT-PCR; the
other half was used to amplify V3 env by nested RT-PCR and so
predict coreceptor use.
Quantification of residual plasma HIV-1. Residual
plasma virus was quantified from the RNA extracted from 6 ml
of plasma using an ultrasensitive real-time RT-PCR assay with a
detection limit of 2.5 copies/ml. The LightCycler RNA master
Hybprobe kit (Roche diagnostics) was used to amplify conserved
sequences within the LTR region using the primers 59-
GGCGCCACTGCTAGAGATTTT-39 and 59-GCCTCAATA-
AAGCTTGCCTTGA-39 and a Taqman probe 59-6Fam-AAG-
TAGTGTGTGCCCGTCTGTTRTKTGACT-Tamra-39. The
amplification mix contained 16 LightCycler RNA master
Hybprobe, 3.25 mM of Mn(OAc)2, 0.3 Unit of Uracil DNA
Glycosylase, 0.5 mM of each primer and 0.25 mM of the Taqman
probe. RT-PCR was performed with the following conditions:
30 min at 59uC; 30 s at 95uC, 5 s at 95uC and 45 s at 62uC for 50
cycles on a LightCycler (Roche diagnostics).
Synthetic HIV-1 RNA was used to generate a standard curve.
Briefly, a 190 bp fragment of the LTR region of HIV-1 HXB2
was inserted into the pGEM-3Z vector downstream of the T7
promoter. The pGEM-3Z recombinant plasmid was linearized
with SmaI, and transcribed with T7 RNA polymerase using the
Riboprobe In Vitro Transcription System (Promega). The
template DNA was digested with RNase-free DNase, and the
RNA transcripts were purified with an RNeasy kit (Qiagen). Serial
dilutions of synthetic HIV-1 RNA were used to generate a
standard curve for each assay. Any DNA contamination was
excluded by performing PCR amplifications without the reverse
transcription step in four patients with detectable residual plasma
virus. The sensitivity of the assay was assessed using plasma
samples containing known copy numbers of HIV-1 (NIBSC HIV-
1 RNA second international standard diluted in HIV-1-seroneg-
ative human plasma).
Determination of the coreceptor usage of residual plasma
HIV-1. The coreceptor usage of the residual virus was
determined genotypically in parallel with its quantification. A
region spanning the V3 region of HIV-1 env was amplified from
the RNA extracted from 6 ml plasma using an ultrasensitive
conventional nested RT-PCR assay with a detection limit of
2.5 copies/ml. RT-PCR was performed with the One-Step RT-
PCR kit (Qiagen), with the following conditions: 30 min at 50uC;
15 min at 95uC; 10 s at 94uC, 30 s at 55uC, and 1 min at 72uC for
50 cycles. Nested PCR was performed with the Expand High
Fidelity Plus PCR System (Roche), with the following conditions:
2 min at 94uC; 30 s at 94uC, 30 s at 55uC, and 30 s at 72uC for 50
cycles. PCRs were performed using 59-ACAATGYACACAT-
GGAATTARGCCA-39 and 59-TTTAATTGTYGAGGYGAA-
TTTTTCT-39 as outer primers and 59- CTGTTAAATGGCAG-
TCTAGC-39 and 59 CCCCTCCACAATTAAAACTGT-39 as
inner primers on a GeneAmp PCR System 9700 (Applied
Biosystems). At least 10 individual molecular clones obtained
using the TOPO-TA cloning kit (Invitrogen, Cergy Pontoise,
France) were sequenced in both directions by the dideoxy
chaintermination method (Big Dye Terminators v.3.1, Applied
Biosystems, Paris, France) on an 3130xl Genetic Analyzer (Applied
Biosystems). Contamination with DNA was ruled out by
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PLoS ONE | www.plosone.org 2 October 2009 | Volume 4 | Issue 10 | e7658performing PCR amplifications without the reverse transcription
step in four patients with detectable residual plasma virus.
We predicted HIV-1 coreceptor usage from the V3 genotype
using a combination of criteria from the 11/25 and net charge
rules, as previously described [45,46].
Characterization of residual HIV-1 in CD14
high CD16
2 and
CD16
+ monocytes
Isolation of CD14
highCD16
2 and CD16
+ monocyte subsets.
Cryopreserved PBMCs (15-25.10
6 cells) were stained with PECy7-
conjugated anti-CD3, ECD-conjugated anti-CD4, PE-conjugated
anti-CD56, AlexaFluor488-conjugated anti-CD14, and PECy5-
conjugated anti-CD16 mAbs (all mAbs were from BD Pharmingen
except the CD3- PECy7 and CD4-ECD mAbs, which were from
Beckman Coulter). Cells were sorted by flow cytometry on an Epics
ALTRA (Beckman-Coulter). Purities were determined by flow
cytometry analysis of the sorted cells on the same instrument with
the same instrument settings. The sorted cells populations were
routinely .99% pure.
Quantification of HIV-1 DNA in the monocyte subsets. A
real-time PCR assay was used to quantify the HIV-1 DNA load
(gag region) from monocyte lysates using fluorescence resonance
energy transfer probes on a LightCycler (Roche Diagnostics), as
previously described [28]. This quantitative PCR assay detects one
copy of HIV-1 DNA in 10
5 cells.
Determination of the coreceptor usage of HIV-1 in the
monocyte subsets. A nested PCR was used to amplify a region
spanning the V3 region of HIV-1 env from monocyte-associated
DNA. Both primary and nested PCRs were performed using the
Expand High Fidelity Plus PCR system (Roche Diagnostics,
Meylan, France). The PCR products from three parallel
amplifications were pooled to prevent sampling bias and cloned
using the TOPO-TA cloning kit (Invitrogen, Cergy Pontoise,
France) and at least 10 individual molecular clones were
sequenced. HIV-1 coreceptor usage was predicted from the V3
genotype using a combination of criteria from the 11/25 and net
charge rules, as previously described [45,46].
Phylogenetic analysis
Multiple alignments were performed with the CLUSTAL W
program, and sequence alignments were edited manually using
BioEdit software. Dendograms were created by the neighbor-
joining method with the Phylogeny Interference Package (PHY-
LIP) and tree diagrams were plotted with the TREEVIEW 1.6.6
program. The HXB2 sequence (GenBank K03455) was included
in all phylogenetic analyses as an outgroup. Maximum likelihood
phylogenies with the same sequence datasets were also estimated
using PhyML 3.0, providing similar tree topologies (data not
shown). The most appropriate nucleotide substitution model for
maximum likelihood phylogenetic analysis was determined with
the model selection procedure implemented in the program
Modeltest 3.7. Bootstrap analysis consisting of 100 replicates was
performed on the phylogenetic trees. Phylogenetic analysis of V3
sequences from the entire PCR products showed distinct clusters
of sequences for each patient that excluded any possibility of
sample contamination or mix-up (data not shown).
Immunological analysis
Sorting of naive T-cell subsets. The CD31
+ and CD31
2
subsets of CD45RA
+ CD27
+ CD4
+ T-cells, and the CD45RA
+
CD27
+ CD8
+ T-cell subset had been sorted in the ANRS EP 32
study by flow cytometry from cryopreserved PBMCs on a MoFlo
cell sorter (Dako-Cytomation, Trappes, France). The sorted cell
populations were routinely better than 99% pure [28].
Flow cytometry analysis. We used the immunophenotypic
analyses that had been previously performed in the ANRS EP 32
study by flow cytometry from cryopreserved PBMCs to measure
the proportion of activated cells among CD4
+ and CD8
+ T-cells
using the HLA-DR and CD38 markers, and the proportion of
CD31
high cells among the CD45RA
+ CD27
+ naı ¨ve CD4
+ T-cells
[28]. Flow cytometric acquisition (0.5–5610
5 events) and analysis
were performed on a Cytomics FC500 driven by the RxP sofware
package (Beckman-Coulter).
TRECs quantification. The sjTREC (dRec-yJa) and each
of the 10 DbJbTRECs (Db1-Jb1.1 to Db1-Jb1.6 and Db2-Jb2.1 to
Db2-Jb2.4) had been measured in the ANRS EP 32 study by
nested quantitative PCR [28]. The sjTREC was quantified in
triplicate and each of the 10 DbJbTRECs in duplicate. The sum of
the DbJbTREC frequencies is 1.3-times the sum of the 10
measured DbJbTREC frequencies (in order to extrapolate to the
13 principal DbJbTRECs). The sj/bTREC ratio is the sjTREC
frequency divided by the sum of DbJbTREC frequencies [47].
Statistical analysis
Quantitative and categorical variables were compared using the
Wilcoxon rank sum test and Fisher’s exact test, respectively.
Correlations between quantitative variables were estimated by
calculating Spearman’s rank correlation coefficient. All tests were
two-tailed, and P values of ,0.05 were considered statistically
significant. Statistical analyses were performed with Stata SE 9.2.
Nucleotide sequence accession numbers
The sequences reported here were given Genbank accession
numbers GU063135 to GU063691.
Results
HIV-1 DNA in CD16
+ and CD14
high CD16
2 monocyte
subsets
Blood monocytes consist of a major CD14
high CD16
2 subset and
a minor CD16
+ subset with distinct phenotypic and functional
characteristics [48–50]. CD16
+ monocytes express more CCR5 on
their surface than do CD14
high CD16
2 monocytes [51,52], and it
has been suggested that the CD16
+ subset could be preferentially
infected by HIV-1 [51,53]. We sorted the CD14
high CD16
2 and
CD16
+ monocyte subsets of the 23 patients from their PBMCs by
flow cytometry (see Fig. S1 for cell sorting of blood monocyte
subsets in the supplemental material). The median percentage of
CD16
+ monocytes was 15.3% (IQR, [11.6–18.4]) of the total
monocytes in the poor immunological responders, and 13.3% (IQR,
[11.9–17.8]) in the good immunological responders (P=0.90).
The short half-life of monocytes in the peripheral blood suggests
that any HIV-1 detected in these cells was due to recent infection
and/or ongoing replication in monocytes or in their precursor cells
despite cART. We used nested PCR to amplify a region spanning
the V3 region of HIV-1 env in the sorted monocyte subsets. Three
amplifications were performed in parallel and pooled to prevent
sampling bias. These data were used for genotypic prediction of
coreceptor usage and phylogenetic analyses. We report the
detection of HIV-1 in the sorted monocyte subsets only for patients
for whom PCR was done on .10
5 sorted cells, i.e. all of the 23
patients for the majority CD14
high CD16
2 monocyte subset, but
onlysevenpatientsfortheminorityCD16
+monocytesubset.HIV-1
DNA was detected in the CD14
high CD16
2 monocytes from five of
the 23 patients (patients 15, 16, 18, 19 and 29), and in the CD16
+
monocytes from two of the seven analyzable patients (patients 22
and 29). One patient (patient 29) had detectable HIV-1 in both
monocyte subsets. We also used real-time PCR with primers that
Residual HIV-1 Viremia
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in the monocyte subsets. The detectable HIV-1 DNA was always
,10copiesper10
6 cells,withoutanysignificantdifferencesbetween
the monocyte subsets (data not shown).
Compartmentalization of HIV-1 between CD14
high
CD16
2 monocytes, CD16
+ monocytes, and CD4
+ T-cells
from patients on effective cART
Molecular env clones obtained from the monocytes of six
patients were compared to the env clones obtained from CD4
+ T-
cells purified by negative magnetic selection from the same
patients. Phylogenetic analysis revealed marked compartmentali-
zation of the HIV-1 quasispecies between the monocytes and the
CD4
+ T-cells in all six patients (the phylogenetic tree of patients 18
and 29 are shown in Fig. 1A and 1B; Fig. S2 in the supplemental
material gives the sequence alignments). HIV-1 was also
compartmentalized between the CD14
high CD16
2 and CD16
+
monocytes in the patient whose HIV-1 DNA had been amplified
from both monocyte subsets (Fig. 1B).
Coreceptor usage of HIV-1 in monocytes from patients
on effective cART
HIV-1 coreceptor usage was genotypically determined from the
V3 amino-acid sequence of the env molecular clones obtained from
the monocyte subsets of six patients; four in the CD14
high CD16
2
subset, one in the CD16
+ monocyte subset, and one in both
monocyte subsets. CXCR4-using viruses were found in the
CD14
high CD16
2 monocytes of four (patients 15, 16, 18, 19) of
five analyzable patients, whereas only CCR5-using viruses were
found in the CD16
+ monocytes of the two analyzable patients
Figure 1. HIV-1 compartmentalization between CD14
high CD16
2 and CD16
+ monocytes. Phylogenetic trees of HIV-1 env sequences
obtained by clonal analysis of PCR products from CD14
high CD16
2 monocytes (open squares), CD16
+ monocytes (open diamonds), and CD4
+ T-cells
(open circles). Blue symbols represent sequences that predict CCR5 coreceptor use; red symbols represent sequences that predict CXCR4 coreceptor
use. The bar indicates genetic distance. Bootstrap values are expressed as percentages for each relevant node and represent the percentage
occurrence of that node calculated using 100 bootstrap replicates. (A) Phylogenetic tree of HIV-1 env sequences of patient 18 (B) Phylogenetic tree of
HIV-1 env sequences of patient 29.
doi:10.1371/journal.pone.0007658.g001
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using viruses in their CD14
high CD16
2 monocytes also harbored
CXCR4-using viruses in their CD4
+ T cells, albeit genetically
distinct (patients 15 and 16), whereas the remaining two patients
had only CCR5-using viruses in their CD4
+ T-cells (patients 18
and 19). The V3 amino-acid sequences of the CXCR4-using
viruses found in the CD14
high CD16
2 monocytes revealed a QR
insertion immediately before the GPGR crown in two patients,
and a net charge of $+7 in three patients (see Fig. S2 in the
supplemental material for sequence alignments).
Residual plasma HIV-1 RNA below 50 copies/ml
The HIV-1 RNA in the plasma of most patients on cART
becomes undetectable by standard assays with a sensitivity of
50 copies/ml. We therefore developed an ultrasensitive RT-PCR
assay to measure HIV-1 RNA in the plasma at concentrations
below 50 copies/ml. This assay reliably detected 2.5 copies/ml, as
assessed using plasma samples containing known copy numbers of
HIV-1 (NIBSC HIV-1 RNA 2nd international standard diluted in
HIV-1-seronegative plasma). The reproducibility and linearity of
the assay was validated in five independent experiments using
serial dilutions of HIV-1 RNA. A plot of the measured values
versus the input HIV-1 RNA was linear (R
2=0.99) across a wide
range of HIV RNA concentrations (see Fig. S3 in the
supplemental material).
We detected low-level viremia in 13 of the 23 patients, more
frequently in the poor immunological responders (8/10 patients)
than in the good immunological responders (5/13 patients)
(P=0.06). Samples with undetectable HIV-1 RNA were assigned
a value half the detection threshold (1.2 copies/ml). The residual
plasma virus load was higher in the poor immunological
responders (median, 6.6 copies/ml, n=10) than in the good
immunological responders (median 1.2 copies/ml, n=13)
(P,0.05) (Fig. 2). The residual plasma virus load on cART was
not significantly correlated with the plasma virus load before the
initiation of cART, nor was it correlated with the nadir of CD4
+
T-cells, and the CD4
+ T-cell count on cART (P.0.10 for all). The
residual HIV-1 RNA load in the plasma was also not correlated
with the HIV-1 DNA load in the PBMCs on cART (r=20.06,
P=0.79) (data not shown).
Coreceptor usage of residual HIV-1 in the plasma on
effective cART
We used a nested RT-PCR with a sensitivity of 2.5 copies/ml to
amplify a region spanning the V3 env region and thus determine
the coreceptor usage of the residual viruses in the plasma. HIV-1
V3 env was successfully amplified from the plasma of 12 of the 23
patients. The env PCR products were cloned and sequenced.
CXCR4-using variants were found in the plasma of 5/12 patients
(three poor and two good immunological responders).
Phylogenetic relationships between the residual HIV-1 in
the plasma and monocytes and CD4
+ T-cells of patients
on effective cART
We first assess the phylogenetic relationships between the
sequences of the viruses present in the plasma, the monocytes, and
the CD4
+ T-cells during cART (see Fig. S2 in the supplemental
material for sequence alignments).
The sequences of the viruses in the plasma of four patients on
cART appeared to be intermixed with the sequences found in the
CD4
+ T-cells (patients 1, 11, 20, 25). For three other patients (6,
15, 16), the sequences present in the plasma were closely related to
some minor CD4
+ clones. Finally, the sequences in the plasma of
four patients (2, 3, 12, 29) were clearly distinct from all of the
sequences found in their CD4
+ T-cells, suggesting that these cells
are not the source of the residual viremia in these patients (see
patients 2 and 3 on Fig. 3). The residual sequences in the plasma
on cART were also compared to those found in circulating
monocytes at this time in three patients (15, 16, 29). Phylogenetic
analysis revealed marked compartmentalization of the HIV-1
quasispecies between these two compartments (see patients 15 and
16 on Fig. 4).
Genetic evolution between ancestral and recent virus
sequences during cART
We next determined whether genetic evolution may have
occurred from the ancestral virus sequences present at baseline in
the plasma and/or the PBMCs to the sequences of recently
produced viruses found in the plasma and the monocytes during
cART. The sequences found in the baseline PBMCs of the nine
patients for whom cell samples were available appeared to be
intermixed with baseline plasma sequences. The residual env
sequences in the plasma of six patients (1, 11, 12, 13, 20, 25) on
cART appeared to be identical or very similar to pre-ART
sequences. By contrast, the phylogenetic analyses suggest genetic
evolution from ancestral to recent sequences during cART for the
other six patients (2, 3, 6, 15, 16, and 29). PBMC samples taken at
baseline were available for three of them (patients 15, 16, and 29).
The HIV-1 env sequences found in the plasma and the monocytes
of these patients after prolonged cART were clearly distinct from
the sequences present in their plasma and cellular reservoirs at
baseline (see patients 15 and 16 on Fig. 4).
Impact of residual viremia on T-cell homeostasis of
patients on cART
We finally assessed the impact of residual viremia on T cell
homeostasis during cART. HIV-1 replication can interfere with
the production of new naı ¨ve T cells by the thymus [54]. The
thymus could also be a site of virus persistence in patients on
cART, and hence a source of residual virus [55,56]. We therefore
assessed the relationship between thymus function, previously
assessed in the patients of the ANRS EP32 study, and the residual
plasma HIV-1. The residual viremia was not significantly
correlated with the intrathymus proliferation rate of immature
thymocytes, as assessed by measuring the sj/bTREC ratio in
PBMCs (r=20.00, P=0.99). But the residual viremia tended to
be negatively correlated with the frequency of recent thymic
emigrants in CD31
+ naive CD4
+-T cells, measured by the
Figure 2. Residual HIV-1 RNA in the plasma. Comparison of the
level of residual HIV-1 RNA in the plasma of the poor (n=10) and good
immunological responders to cART (n=13).
doi:10.1371/journal.pone.0007658.g002
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+ naı ¨ve-cell subset
(r=20.37, P=0.08) (Fig. 5A). There was a similar tendency to a
negative correlation with the frequency of sjTREC-bearing cells in
the naı ¨ve CD8
+ T-cell subset (r=20.41, P=0.05, data not
shown). Finally, the residual viremia also tended to be negatively
correlated with the absolute number of recent thymic emigrants
per mm
3 of blood, defined by a CD31
high phenotype among the
naı ¨ve CD4
+ T-cells (r=20.36, P=0.09) (Fig. 5B). This tendency
to fewer recent thymic emigrants in the peripheral blood of those
patients who have the highest residual viremia was not linked to
HIV-1 coreceptor usage, nor did it differ between the poor and
good immunological responders (data not shown). Furthermore,
there were significant genetic differences between the residual
virus sequences found in the plasma and the sequences found in
the CD31
+ naı ¨ve CD4
+ T-cells during cART (data not shown).
These results, therefore, do not indicate that the thymus is a source
of the residual viruses found in the plasma.
We have previously shown that poor immune reconstitution of
patients on cART is strongly correlated with persistent T-cell
activation rather than with thymus dysfunction [28]. Residual
virus replication despite cART could be one of the drivers of
persistent T-cell activation. We therefore assessed the association
between residual viremia and persistent T-cell activation in
patients on cART with a sustained plasma virus load of
,50 copies/ml. The level of residual viremia was correlated
with the frequency of HLA-DR
+ CD4
+ T-cells (r=0.41,P=0.05)
and of HLA-DR
+ CD38
+ CD8
+ T-cells (r=0.40,P=0.06) (data
not shown). As the residual viremia was greater in the poor
Figure 3. Difference between plasma and CD4
+ T-cells viruses during cART and plasma viruses at baseline. Phylogenetic trees of HIV-1
env sequences obtained by clonal analysis of PCR products from CD4
+ T-cells (open circles), plasma on cART (open triangles) and plasma at baseline
(closed triangles). Blue symbols represent sequences that predict CCR5 coreceptor use; red symbols represent sequences that predict CXCR4
coreceptor use. The bar indicates genetic distance. Bootstrap values are expressed as percentages for each relevant node and represent the
percentage occurrence of that node calculated using 100 bootstrap replicates. (A) Phylogenetic tree of HIV-1 env sequences of patient 2 (B)
Phylogenetic tree of HIV-1 env sequences of patient 3.
doi:10.1371/journal.pone.0007658.g003
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responders,we theninvestigatedtherelationship betweenresidual
viremia and T-cell activation in the two groups separately. The
level of residual viremia was significantly correlated with the
frequency of activated CD4
+ T-cells (r=0.71, P,0.05) in the
poor immunological responders (Fig. 5C), but not in the good
immunological responders (r=-0.26, P=0.38) (Fig. 5D). Simi-
larly, the level of residual viremia was significantly correlated with
the frequency of activated CD8
+ T-cells in the poor immunolog-
ical responders (r=0.71, P,0.05), but not in the good
immunological responders (r=20.12, P=0.70) (data not shown).
These results suggest that low-level HIV-1 viremia may
contribute to persistent T-cell activation and poor immune
reconstitution despite cART.
Figure 4. Genetic evolution of HIV-1 despite effective cART. Phylogenetic trees of HIV-1 env sequences obtained from CD14
high CD16
2
monocytes (open squares), CD4
+ T-cells (open circles), and plasma (open triangles) during cART, and plasma (closed triangles) and PBMCs (closed
stars) at baseline before starting cART. Blue symbols represent sequences that predict CCR5 coreceptor use; red symbols represent sequences that
predict CXCR4 coreceptor use. The bar indicates genetic distance. Bootstrap values are expressed as percentages for each relevant node and
represent the percentage occurrence of that node calculated using 100 bootstrap replicates. (A) Phylogenetic tree of HIV-1 env sequences of patient
16 (B) Phylogenetic tree of HIV-1 env sequences of patient 15.
doi:10.1371/journal.pone.0007658.g004
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We have investigated the residual replication of HIV-1 in 23
patients that were receiving sustained effective cART for a median
duration of seven years. Residual plasma virus below 50 copies per
ml was detected in 8 of 10 patients with poor CD4
+ T-cell
reconstitution in response to cART, and in only 5 of 13 patients
with good CD4
+ T-cell reconstitution. This confirms previous
reports [1–7] that low-level virus production can continue in
patients despite their being on long-term effective cART. Our
results further suggest that this residual viremia could have a
significant impact on the immunological parameters of some
patients on sustained effective cART.
One important issue for assessing virus populations based on
PCR products is the use of a sufficient number of templates. To
limit resampling bias in this study, we ultracentrifuged 6 ml of
plasma to characterize the residual plasma viremia. As the levels of
residual HIV-1 RNA detected in the plasma ranged from 2.5 to
29.7 copies/ml,we can thus estimate that 15 to 180 copies of HIV-
1 were subjected to V3 env PCR in these patients. Moreover, there
was significant genetic diversity in the residual viruses found in the
plasma of some patients, despite their residual viremia being rather
low. In contrast, there was little genetic diversity in the residual
viruses found in the plasma of most patients despite their higher
residual viremia. This finding of a homogenous virus population in
the plasma of most of the patients on effective cART is in
agreement with other reports. In a study designed to avoid PCR
resampling using intensive sampling, Bailey et al. found a
predominant plasma clone in most of the patients with
treatment-induced viral loads below 50 copies/ml [1]. Indeed,
despite wide diversity of HIV-1 sequences in resting CD4
+ T-cells,
they found that residual virus in plasma was dominated by a
homogeneous population with identical pol and env sequences.
We investigated the cellular sources of the low-level viremia that
persists during cART and found that the residual viruses in the
plasma of most patients on long-term effective cART were
phylogenetically similar to the viruses in their CD4
+ T-cells, the
major cellular reservoir of HIV-1. But, in agreement with others
[1,57], our results also suggest that the CD4
+ T-cells are probably
not the only source of the residual viruses in the plasma of some
patients. Several reports have suggested that blood monocytes are
one of the sources of the viruses in the plasma of patients on cART
[32,57]. However, we find that the viruses in the plasma and
monocytes on cART are clearly different, suggesting that these
cells were not the source of the residual plasma viruses. As both
compartments are probably replenished by recently produced
viruses, there could be at least two sources of residual virus in
patients on effective cART. Circulating monocytes are thought to
reflect recent infection because of their short half-life in the
peripheral blood [36,37]. But a stable latent infection of some of
their bone marrow progenitors might challenge this view.
However, despite some controversy, hematopoietic CD34
+ stem
cells do not appear to be frequently infected by HIV-1 in vivo
[58–60]. By contrast, HIV-1 could infect further committed
monocytic progenitors and contribute to the presence of HIV-1
DNA in circulating monocytes (reviewed in [61]). These
committed hematopoietic progenitors have lost their self-renewal
capacity and have a short half-life before terminally differentiating
into blood monocytes [36,37]. Hence, they cannot be a stable
latent reservoir for HIV-1. While we cannot determine whether
Figure 5. Correlation between residual viremia and immunological parameters of CD4
+ T-cell homeostasis. (A) Correlation between the
residual plasma virus concentration and the frequency of sjTREC-bearing cells in the CD31
+ subset of naı ¨ve CD4
+ T-cells; (B) Correlation between the
residual plasma virus concentration and the absolute numbers of CD31
high naı ¨ve CD4
+ T-cells per mm
3 of blood; (C and D) Correlation between the
residual plasma virus concentration and CD4
+ T-cell activation in the poor and good immunological responders.
doi:10.1371/journal.pone.0007658.g005
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after their release in the peripheral blood, they probably reflect
recently produced viruses. A longitudinal study reported that the
virus sequences found in blood monocytes continuously evolve
faster during cART than the virus sequences found in the CD4
+ T
cell compartment, which is in favor of the labile status of the
viruses found in circulating monocytes [34].
Low-level viremia could arise from the release of archival virus
from latent cellular reservoirs established before cART or from
low-levels of complete cycles of virus replication. Whether ongoing
low-level virus replication may persist despite apparently effective
cART remains controversial, as previous studies have obtained
conflicting results. The residual plasma HIV-1 RNA load has been
reported to decrease following treatment intensification with
abacavir [3]. Similarly, a transient increase in unintegrated
episomal forms of cell-associated HIV-1 DNA was observed
following treatment intensification with raltegravir [62]. However,
studies suggesting that virus replication may persist despite cART
are challenged by others that found no effect of treatment
intensification on the residual plasma HIV-1 RNA load [63–66].
Our results suggest that both viral expression from cellular
reservoirs and ongoing viral replication may occur on cART. Half
of the patients in our study showed no significant difference
between the ancestral viruses found in their plasma and PBMCs at
baseline before starting cART and the residual viruses in their
plasma after they had been on cART. These findings are thus
compatible with the sporadic release of ancestral viruses archived
in cellular reservoirs into the plasma without any significant
genetic evolution in these patients during cART, in agreement
with previous reports [15–17,66,67]. By contrast, phylogenetic
analyses suggest that there was genetic evolution of the virus
sequences in six patients, despite their being on cART. The
sequences of ancestral viruses in baseline plasma and PBMCs had
evolved to those of recent viruses found in the plasma and
monocytes of these patients on cART. The genetic evolution from
ancestral to recent sequences in these patients suggests that there
can still be cycles of virus replication in some patients despite
apparently effective cART.
While the absence of significant residual virus replication and
genetic evolution during cART is probably the most frequent
pattern, the ongoing virus replication despite cART suggested by
our results might be due to some particular characteristics of the
subjects studied here. They are not representative of the general
populationofHIV-infectedindividuals,butwereselectedbecauseof
their markedly different phenotypes of poor and good immunolog-
ical reconstitution in response to cART. They also have different
virological characteristics, with CXCR4-using viruses being fre-
quent in the poor immunological responders [28]. Allthe patients in
this study with a pattern suggesting ongoing virus replication and
genetic evolution during cART harbored CXCR4-using viruses.
This suggests a link between ongoing virus replication during cART
and virus tropism for CXCR4.
We previously reported that cART seems to favor the progressive
selection of pre-existing minor CXCR4-viruses that were already
present in baseline quasispecies [43]. Other studies have also reported
an increased frequency of CXCR4-using viruses in patients on cART
[68-70]. How cART might favor the residual replication of CXCR4-
using viruses remains unknown. One study reported that the
expression of CXCR4 was correlated with the presence of P-
glycoprotein in CD4
+ T lymphocytes [71]. CXCR4-bearing cells
could thus be a pharmacological sanctuary. Alternatively, the
lymphoid microenvironment could provide a selective advantage
for the replication of CXCR4-using viruses during cART, in parallel
with changes in T-cell homeostasis during immune reconstitution.
Our results also suggest that the CD14
high CD16
2 monocytes
could play a role in the emergence of CXCR4-using viruses during
cART. We found an unexpectedly high frequency of CXCR4-
using viruses in the CD14
high CD16
2 monocytes, even in some
patients who had only CCR5-using viruses in their CD4
+ T-cells.
By contrast, all the molecular env clones from CD16
+ monocytes
were predicted to use CCR5. This could be due to different levels
of expression of the HIV-1 entry coreceptor on the surfaces of
these two monocyte subsets. CD16
+ monocytes bear two to five
times more CCR5 and two to four times less CXCR4 than do
CD14
high CD16
2 monocytes [51].
The residual replication of CXCR4-using viruses could interfere
with both thymus activity and peripheral T-cell homeostasis as
thymocytes and naı ¨ve CD4
+ T-cells mainly bear the CXCR4
coreceptor for HIV-1 [44,55,72]. We find a tendency to fewer
recent thymic emigrants in the peripheral blood of those patients
with the highest residual viremia. HIV-1 replication can interfere
with the production of new naı ¨ve T-cells by the thymus, either
directly by infecting immature or mature CD4
+ thymocytes [55],
or indirectly by reducing the proliferation of T-cell precursors
within the thymus, due to inhibition by certain cytokines, notably
interferon-a [73]. However, the ANRS EP32 study showed that
the infection of CD4
+ thymocytes and their export into the
peripheral circulation is probably rare in patients on effective
cART. Most of the infectious events in naı ¨ve CD4
+ T-cells seem to
occur during the peripheral proliferation of these cells, as
suggested by the finding of more virus in the CD31
2 naı ¨ve
CD4
+ T-cells that have proliferated in the periphery than in the
CD31
+ subset that contains the recent thymic emigrants [28]. We
found that the sequences of the viruses in the CD31
+ naı ¨ve CD4
+
T-cells were different from those in the plasma, suggesting that the
thymus is probably not a source of the residual virus in the plasma
of patients on cART. Furthermore, our data do not support the
idea that the residual viremia inhibits thymus output via a cytokine
pathway. We found no negative correlation between the residual
viremia and the intrathymic proliferation of immature thymocytes,
measured by the sj/bTREC ratio. Thus, the residual viremia does
not seem to inhibit thymus output, either directly or indirectly. But
the tendency for there to be fewer recent thymic emigrants in the
peripheral blood of those patients with the highest residual viremia
might be best explained by their sequestration in secondary
lymphoid organs, as in viremic patients [74,75]. Unfortunately,
biopsies of the lymph nodes of the patients in the ANRS EP32
study were not available to confirm this hypothesis.
Our previous study comparing the virological and immunolog-
ical features of these patients showed that poor immunological
reconstitution despite effective cART was strongly correlated with
persistent T-cell activation rather than with thymus disfuction
[28]. The reports on the capacity of residual virus replication
despite cART to drive persistent T-cell activation are conflicting.
The presence of the CD38 marker of activation on CD8
+ T-cells is
correlated with the HIV-1 RNA load in the plasma and declines
during cART. It has thus been suggested that the persistence of
increased frequencies of CD38
high CD8
+ T-cells in patients on
effective cART reflects residual virus replication [76,77]. One
study [3] showed that some markers of cell activation were
reduced in both CD4
+ and CD8
+ T-cells following intensified
antiretroviral treatment. The residual viremia was also associated
with immune activation, as indicated by soluble blood markers but
not by cellular markers of immune activation [78]. By contrast,
another recent study found no association between the percentage
of CD38
high CD8
+ T-cells and the residual plasma virus, although
CD8
+ T-cell activation was negatively correlated with the CD4
+
T-cell count [79]. Our data indicate that there is more residual
Residual HIV-1 Viremia
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in that of good immunological responders. We also find that the
residual viremia in the poor immunological responders was
positively correlated with the activation of their CD4
+ and
CD8
+ T-cells, as assessed by the HLA-DR and CD38 markers.
The ongoing low-level virus production despite cART in some
patients might thus contribute to persistent immune activation.
We have characterized the residual viruses that are still
produced in HIV-infected patients despite their being on sustained
effective cART for a median duration of seven years. We find
evidence that the residual viremia could be due to the release of
archival virus from reservoir cells and/or ongoing virus replication
in some patients. The compartmentalization of recently produced
viruses between the plasma and the blood monocytes suggests that
there are at least two sources of the residual virus found in patients
on effective cART. Moreover, other cellular sources of viruses, in
addition to the main CD4
+ T-cell reservoir, could also contribute
to the plasma residual viruses. CXCR4-using viruses were
frequent among the recently produced viruses in the plasma and
in the main CD14
high CD16
2 monocyte subset, suggesting that
these variants might be produced preferentially in patients on
cART. Finally, our data strongly suggest that low-level virus
production might contribute to persistent immune dysfunction in
some patients, despite cART.
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